Literature DB >> 8593713

Nail incorporation kinetics of terbinafine in onychomycosis patients.

F Schatz1, M Bräutigam, E Dobrowolski, I Effendy, H Haberl, H Mensing, G Weidinger, A Stütz.   

Abstract

Patients with toe-nail onychomycosis were treated with terbinafine (250 mg daily, n = 20) for either 6 or 12 weeks in a randomized double-blind study. Plasma and distal nail clippings were taken before initiation of therapy and 1, 6, 12, 18, 24, 36 and 48 weeks thereafter. Analytical data of terbinafine extracted from nail clippings or plasma were obtained by high-performance liquid chromatography (HPLC). Nail extracts and isolated HPLC terbinafine peaks were analysed using a combined gas chromatography-mass spectroscopy system (GC-MS) for unequivocal identification of the drug. Terbinafine could be detected in the distal nail in the majority of the patients within 1 week of starting therapy. Maximum terbinafine levels of 0.52 and 1.01 micrograms/g were measured after 18 weeks in the 6- and 12-week treatment groups, respectively. While plasma levels decreased rapidly after termination of therapy terbinafine was detected in the nails as long as 30 weeks (6 weeks treatment) and 36 weeks (12 weeks treatment) after termination of therapy at a range of 0.28-0.19 microgram/g. The drug concentrations measured at all time points are well above the minimum inhibitory concentration (MIC) for dermatophytes and other fungi. These data suggest that the drug reaches the nail plate rapidly and persists there for several months after cessation of active treatment.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8593713     DOI: 10.1111/j.1365-2230.1995.tb01353.x

Source DB:  PubMed          Journal:  Clin Exp Dermatol        ISSN: 0307-6938            Impact factor:   3.470


  11 in total

Review 1.  Oral antifungal medication for toenail onychomycosis.

Authors:  Sanne Kreijkamp-Kaspers; Kate Hawke; Linda Guo; George Kerin; Sally Em Bell-Syer; Parker Magin; Sophie V Bell-Syer; Mieke L van Driel
Journal:  Cochrane Database Syst Rev       Date:  2017-07-14

Review 2.  A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis.

Authors:  A K Gupta; N H Shear
Journal:  Drug Saf       Date:  2000-01       Impact factor: 5.606

3.  In vitro activities of terbinafine against cutaneous isolates of Candida albicans and other pathogenic yeasts.

Authors:  N S Ryder; S Wagner; I Leitner
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191

Review 4.  Pharmacokinetics of antifungal agents in onychomycoses.

Authors:  D Debruyne; A Coquerel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group.

Authors:  E G Evans; B Sigurgeirsson
Journal:  BMJ       Date:  1999-04-17

Review 6.  Terbinafine. An update of its use in superficial mycoses.

Authors:  K J McClellan; L R Wiseman; A Markham
Journal:  Drugs       Date:  1999-07       Impact factor: 9.546

Review 7.  Management of onychomycoses.

Authors:  M Niewerth; H C Korting
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

8.  [Modern antimycotics. What the treating physician needs to know].

Authors:  C Seebacher
Journal:  Hautarzt       Date:  2004-02       Impact factor: 0.751

9.  Pathogenic Dermatophytes Survive in Nail Lesions During Oral Terbinafine Treatment for Tinea Unguium.

Authors:  Tomoyuki Iwanaga; Tsuyoshi Ushigami; Kazushi Anzawa; Takashi Mochizuki
Journal:  Mycopathologia       Date:  2017-03-09       Impact factor: 2.574

10.  Prolonged Drug-Drug Interaction between Terbinafine and Perphenazine.

Authors:  Young-Min Park
Journal:  Psychiatry Investig       Date:  2012-11-12       Impact factor: 2.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.